Mallinckrodt PLC (NYSE:MNK) VP Steven J. Romano bought 1,000 shares of the firm’s stock in a transaction on Friday, June 9th. The stock was purchased at an average price of $39.88 per share, for a total transaction of $39,880.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of Mallinckrodt PLC (MNK) traded up 4.65% during midday trading on Monday, reaching $43.64. 1,633,326 shares of the company traded hands. The company’s 50 day moving average is $43.16 and its 200-day moving average is $47.66. The stock’s market capitalization is $4.34 billion. Mallinckrodt PLC has a 12 month low of $38.80 and a 12 month high of $85.83.
Mallinckrodt PLC (NYSE:MNK) last posted its quarterly earnings data on Monday, May 8th. The company reported $1.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.63 by $0.05. The company had revenue of $810.90 million for the quarter, compared to analyst estimates of $781.23 million. Mallinckrodt PLC had a net margin of 16.01% and a return on equity of 16.33%. The business’s quarterly revenue was down .6% on a year-over-year basis. During the same quarter last year, the firm posted $2.01 earnings per share. Equities research analysts forecast that Mallinckrodt PLC will post $7.55 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Mallinckrodt PLC (MNK) VP Acquires $39,880.00 in Stock” was originally posted by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://baseballnewssource.com/markets/mallinckrodt-plc-mnk-vp-purchases-39880-00-in-stock-updated/985463.html.
Several equities analysts have weighed in on MNK shares. Leerink Swann reiterated an “outperform” rating on shares of Mallinckrodt PLC in a report on Monday, March 20th. Canaccord Genuity started coverage on shares of Mallinckrodt PLC in a report on Tuesday, February 21st. They issued a “buy” rating and a $91.00 target price on the stock. Jefferies Group LLC lowered shares of Mallinckrodt PLC to a “buy” rating and decreased their target price for the company from $95.00 to $70.00 in a report on Monday, March 13th. Deutsche Bank AG set a $68.00 target price on shares of Mallinckrodt PLC and gave the company a “buy” rating in a report on Wednesday, May 31st. Finally, Vetr lowered shares of Mallinckrodt PLC from a “hold” rating to a “sell” rating and set a $51.34 target price on the stock. in a report on Monday, February 20th. One analyst has rated the stock with a sell rating, six have issued a hold rating and fifteen have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $74.31.
Hedge funds have recently bought and sold shares of the stock. Gamco Investors INC. ET AL raised its stake in Mallinckrodt PLC by 20.5% in the fourth quarter. Gamco Investors INC. ET AL now owns 17,425 shares of the company’s stock worth $868,000 after buying an additional 2,963 shares in the last quarter. Elkfork Partners LLC purchased a new stake in Mallinckrodt PLC during the fourth quarter worth about $3,633,000. Marshall Wace LLP raised its stake in Mallinckrodt PLC by 342.7% in the fourth quarter. Marshall Wace LLP now owns 24,450 shares of the company’s stock worth $1,218,000 after buying an additional 18,927 shares in the last quarter. Trexquant Investment LP raised its stake in Mallinckrodt PLC by 200.3% in the fourth quarter. Trexquant Investment LP now owns 34,834 shares of the company’s stock worth $1,735,000 after buying an additional 23,234 shares in the last quarter. Finally, Pinnacle Associates Ltd. raised its stake in Mallinckrodt PLC by 13.4% in the fourth quarter. Pinnacle Associates Ltd. now owns 5,703 shares of the company’s stock worth $284,000 after buying an additional 675 shares in the last quarter. Institutional investors own 96.96% of the company’s stock.
Mallinckrodt PLC Company Profile
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
Receive News & Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related companies with our FREE daily email newsletter.